EC approves Abilify for bipolar I disorder

The European Commission granted marketing approval for Abilify aripiprazole from Bristol-Myers (NYSE:BMY) and Otsuka (Tokyo:4768) to treat and prevent moderate to severe manic episodes in bipolar I di...